ex10-4.htm


    Exhibit 10.4


     

    SECURITY
AGREEMENT

     

     

    (Patent)

     

    THIS SECURITY AGREEMENT
(PATENT) (“Agreement”), is
entered into and made effective as of August 8, 2008, by and between IR BIOSCIENCES HOLDINGS, INC.,
a Delaware corporation with its principal place of business located at
8767 E. Via De Ventura, Suite 190, Scottsdale, AZ 85258 (the “Parent”), and the
each subsidiary of the Parent listed on Schedule I attached hereto (each a
“Subsidiary,”
and collectively and together with the Parent, the “Company”), in favor
of Brencourt Advisors, LLC as agent (the “Secured Party”) for
the holders of the Convertible Debentures referred to in the following paragraph
(the “Holders”).

     

     

    WITNESETH:

     

    WHEREAS, in connection with
the Securities Purchase Agreement by and among the Parent and the Secured Party
of even date herewith (the “Securities Purchase
Agreement”), the Parent has agreed, upon the terms and subject to the
conditions of the Securities Purchase Agreement, to issue to the Holders (i) an
aggregate original principal amount of up to $5,000,000 of senior secured
convertible debentures (the “Convertible
Debentures”), which shall be convertible into shares of the Parent’s
Common Stock (the “Conversion Shares”);
and (ii) warrants (the “Warrants”) to be
exercisable to acquire additional shares of Common Stock (the “Warrants Shares”)
initially in that number of shares of Common Stock set forth in the Securities
Purchase Agreement;

     

    WHEREAS, to induce each Holder
to purchase the Convertible Debentures and enter into the Securities Purchase
Agreement and the documents entered into in connection therewith, (collectively
referred to as the “Transaction
Documents”), each Company hereby grants to the Secured Party a security
interest, in and to the Patent Collateral (as defined below) to secure all of
the Obligations (as defined below).

     

    WHEREAS, in connection with
the Securities Purchase Agreement, each Company has agreed to provide the
Secured Party a general security interest in the Pledged Property (as this term
is defined in the Security Agreement by and between each Company and the Secured
Party, dated August 8, 2008 (together with all amendments, supplements,
restatements and other modifications, if any, from time to time made thereto,
the “Security
Agreement”);

     

    WHEREAS, each Company has duly
authorized the execution, delivery and performance of this
Agreement;

     

    NOW THEREFORE, for good and
valuable consideration, the receipt of which is hereby acknowledged, the Company
agrees as follows:

     

    SECTION
1. Definitions.  Unless
otherwise defined herein otherwise requires, terms used in this Agreement,
including its preamble and recitals, have the meanings provided in the
Securities Purchase Agreement.

     

    (a) “Obligations” shall have the
meaning assigned to it in the Security Agreement.

     

    SECTION
2. Grant of Security
Interest.  For good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, to secure the payment and
performance of all of the Obligations of the Company, the Company does hereby
mortgage, pledge and hypothecate to the Secured Party and grant to the Secured
Party a security interest in all of the following property (the “Patent Collateral”), now owned
and existing:

     

    (a) all
letters patent and applications for letters patent throughout the world,
including all patent applications in preparation for filing anywhere in the
world and including each patent and patent application referred to in Schedule A
hereto;

     

    (b) all
reissues, divisions, continuations, continuations-in-part, extensions, renewals
and reexaminations of any of the items described in clause (a);

     

    (c) all
patent licenses and other agreements providing the Company with the right to use
any of the items of the type referred to in clauses (a) and (b), including each
patent license referred to in Schedule A
hereto;

     

    (d) the right
to sue third parties for past, present or future infringements of any Patent
Collateral described in clauses (a) and (b) and, to the extent applicable,
clause (c); and

     

    (e) all
proceeds of, and rights associated with, the foregoing, (including license
royalties and proceeds of infringement suits), and all rights corresponding
thereto throughout the world.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    SECTION
3. Security
Agreement.  This Agreement has been executed and delivered by
each Company for the purpose of recording the security interest of the Secured
Party in the Patent Collateral relating to patents referred to in Schedule A with the
United States Patent and Trade Marks Office, to the extent it may be so
registered therein.  The security interest granted hereby has been
granted as a supplement to, and not in limitation of, the security interest
granted to the Secured Party under the Security Agreement.  The
Security Agreement (and all rights and remedies of the Secured Party thereunder)
shall remain in full force and effect in accordance with its terms.

     

    SECTION
4. Release of Security
Interest.  Upon payment in full of all Obligations the Secured
Party shall, at the Company’s expense, execute and deliver to the Company all
instruments and other documents as may be necessary or proper to release the
lien on any security interest in the Patent Collateral which has been granted
hereunder.

     

    SECTION
5. Acknowledgement.  The
Company does hereby further acknowledge and affirm that the rights and remedies
of the Secured Party with respect to the security interest in the Patent
Collateral granted hereby are more fully set forth in the Security Agreement,
the terms and provisions of which (including the remedies provided for therein)
are incorporated by references herein as if fully set forth herein.

     

    SECTION
6. Securities Purchase
Agreement.  Notwithstanding any other term or provision hereof,
in the event that any provisions hereof contradict and are incapable of being
construed in conjunction with the provisions of the Securities Purchase
Agreement, the provisions of the Securities Purchase Agreement shall take
precedence over those contained herein and, in particular, if any act of the
Company is expressly permitted under the Securities Purchase Agreement but is
prohibited hereunder, any such act shall be permitted hereunder and any
encumbrance expressly permitted under the Securities Purchase Agreement to exist
or to remain outstanding shall be permitted hereunder and thereunder. This
instrument, document or agreement may be sold, assigned or transferred by the
Agent in accordance with the terms of the Securities Purchase
Agreement.

     

    SECTION
7. Counterparts.  This
Agreement may be executed by the parties hereto in several counterparts, each of
which shall be deemed to be an original and all of which shall constitute
together but one and the same agreement.

     

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    IN WITNESS WHEREOF, the
parties hereto have executed this Security Agreement as of the date first above
written

     

    
      	 
      	
              IR
      Biosciences Holdings, Inc.

            
	 
      	 
      
	 
      	
              By:       /s/ Michael
      Wilhelm               
      

            
	 
      	
              Name:  Michael
      Wilhelm

            
	 
      	
              Title:    CEO

            


    

     

    IN WITNESS WHEREOF, the
parties hereto have executed this Security Agreement as of the date first above
written.

    


    
      	 
      	
              COMPANY:

            
	 
      	
              ImmuneRegen
      BioSciences, Inc.

            
	 
      	 
      
	 
      	
              By:      /s/ Michael
      Wilhelm                  

            
	 
      	
              Name:  Michael
      Wilhelm

            
	 
      	
              Title:    CEO

            


    

    


     

     IN WITNESS WHEREOF, the
parties hereto have executed this Security Agreement as of the date first above
written.

     

    
      	 
      	
              SECURED
      PARTY:

            
	 
      	
              Brencourt
      Multi-Strategy Master Ltd.

            
	 
      	 
      
	 
      	
              By:  Brencourt
      Advisors, LLC, its investment manager

            
	 
      	 
      
	 
      	
              By:      
      /s/ Michael
      Palmer                                                                

            
	 
      	
              Name:  Michael
      Palmer

            
	 
      	
              Title:    Chief
      Financial Officer

            


    

    


    IN WITNESS WHEREOF, the
parties hereto have executed this Security Agreement as of the date first above
written.

    


    
      	 
      	
              SECURED
      PARTY:

            
	 
      	
              Brencourt
      Multi-Strategy Enhanced Dedication Fund, L.P.

            
	 
      	 
      
	 
      	
              By:  Brencourt
      Advisors, LLC, its investment manager

            
	 
      	 
      
	 
      	
              By:      /s/ Michael
      Palmer                             

            
	 
      	
              Name: Michael
      Palmer

            
	 
      	
              Title:   Chief
      Financial Officer

            


    

    


    IN WITNESS WHEREOF, the
parties hereto have executed this Security Agreement as of the date first above
written.

    


    
      	 
      	
              SECURED
      PARTY:

            
	 
      	
              Man
      Mac Schreckhorn 14B Limited

            
	 
      	 
      
	 
      	
              By:  Brencourt
      Advisors, LLC, its investment manager

            
	 
      	 
      
	 
      	
              By:      /s/ Michael
      Palmer                           

            
	 
      	
              Name: Michael
      Palmer

            
	 
      	
              Title:   Chief
      Financial Officer

            


    

     

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    SCHEDULE
I

    


    


    LEGAL NAMES; ORGANIZATIONAL
IDENTIFICATION NUMBERS; STATES OF ORGANIZATION

    


    


    


    The
Company has one wholly-owned subsidiary:

    


    ImmuneRegen
BioSciences, Inc.

    8767 E.
Via De Ventura, Suite 190

    Scottsdale,
Arizona 85258

     

    
      
        	
                 

                Company’s
      Name

              	
                State
      of Organization

              	
                Employer
      ID

              	
                Organizational
      ID

              
	
                IR
      Biosciences Holdings, Inc.

              	
                Delaware

              	
                13-3301889

                 

              	
                2063399

                 

              
	
                ImmuneRegen
      BioSciences, Inc.

              	
                Delaware

              	
                11-3666487

              	
                3585852

                 

              


      

    

     

     

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    


    SCHEDULE
A

    


    PATENTS AND
APPLICATIONS

    


    
      
        	
                TITLE

              	
                COUNTRY

              	
                FILING
      DATE

              	
                APPLICATION
      NUMBER

              	
                DATE
      ISSUED

              	
                PATENT
      NUMBER

              
	
                Substance
      P Treatment for Immunostimulation

              	
                United
      States of America

              	
                23-Feb-98

              	
                09/028003

              	
                7-Dec-99

              	
                5998376

              
	
                Substance
      P Treatment for Immunostimulation

              	
                United
      States of America

              	
                28-Mar-97

              	
                08/829445

              	
                31-Aug-99

              	
                5945508

              
	
                Substance
      P Treatment for Immunostimulation

              	
                Australia

              	
                8-Jul-97

              	
                40464/97

              	
                22-Nov-01

              	
                737201

              
	
                Substance
      P Treatment for Immunostimulation

              	
                Canada

              	
                8-Jul-97

              	
                2261885

              	 
      	 
      
	
                Substance
      P Treatment for Immunostimulation

              	
                Switzerland

              	
                8-Jul-97

              	
                97938049

              	
                24-Mar-04

              	
                957930

              
	
                Substance
      P Treatment for Immunostimulation

              	
                Germany

              	
                8-Jul-97

              	
                97938049

              	
                24-Mar-04

              	
                957930

              
	
                Substance
      P Treatment for Immunostimulation

              	
                France

              	
                8-Jul-97

              	
                97938049

              	
                24-Mar-04

              	
                957930

              
	
                Substance
      P Treatment for Immunostimulation

              	
                Spain

              	
                8-Jul-97

              	
                97938049

              	
                24-Mar-04

              	
                957930

              
	
                Substance
      P Treatment for Immunostimulation

              	
                United
      Kingdom

              	
                8-Jul-97

              	
                97938049

              	
                24-Mar-04

              	
                957930

              
	
                Substance
      P Treatment for Immunostimulation

              	
                Ireland

              	
                8-Jul-97

              	
                97938049

              	
                24-Mar-04

              	
                957930

              
	
                Substance
      P Treatment for Immunostimulation

              	
                Italy

              	
                8-Jul-97

              	
                97938049

              	
                24-Mar-04

              	
                957930

              
	
                Substance
      P Treatment for Immunostimulation

              	
                Liechtenstein

              	
                8-Jul-97

              	
                97938049

              	
                24-Mar-04

              	
                957930

              
	
                Substance
      P Treatment for Immunostimulation

              	
                Monaco

              	
                8-Jul-97

              	
                97938049

              	
                24-Mar-04

              	
                957930

              
	
                Amelioration
      of Effects of Cigarette Smoke

              	
                United
      States of America

              	
                22-Aug-03

              	
                10/645,839

              	 
      	 
      
	
                Amelioration
      of Effects of Cigarette Smoke

              	
                Singapore

              	
                22-Aug-03

              	
                200501072-3

              	 
      	 
      
	
                Amelioration
      of Effects of Cigarette Smoke

              	
                China

              	
                22-Aug-03

              	
                3820184.4

              	 
      	 
      
	
                Amelioration
      of Effects of Cigarette Smoke

              	
                Japan

              	
                22-Aug-03

              	
                2004-532943

              	 
      	 
      
	
                Amelioration
      of Effects of Cigarette Smoke

              	
                European
      Patent Office

              	
                22-Aug-03

              	
                3791722.6

              	 
      	 
      
	
                Amelioration
      of Effects of Cigarette Smoke

              	
                Canada

              	
                22-Aug-03

              	
                2496447

              	 
      	 
      
	
                Use
      of Substance P or a Bioactive  Analog Thereof for Production
      of  Medicament for Ameliorating or Preventing Damage Caused by
      Cigarette Smoke

              	
                Vietnam

              	
                22-Aug-03

              	
                1-2005-00215

              	 
      	 
      
	
                Acute
      Respiratory Syndromes

              	
                Hong
      Kong

              	
                22-Jun-06

              	
                6107144.4

              	 
      	 
      
	
                Acute
      Respiratory Syndromes

              	
                European
      Patent Office

              	
                14-Apr-04

              	
                4759500.4

              	 
      	 
      
	
                Acute
      Respiratory Syndromes

              	
                United
      States of America

              	
                14-Oct-05

              	
                10/553,232

              	 
      	 
      
	
                Acute
      Respiratory Syndromes

              	
                Singapore

              	
                14-Apr-04

              	
                200507608-8

              	 
      	 
      
	
                Use
      of Substance P or its Analogs for the Manufacture of Medicaments for
      Treating or Protecting SARS or ARDS

              	
                Vietnam

              	
                14-Apr-04

              	
                1-2005-01560

              	 
      	 
      
	
                Prevention
      of Respiratory Infections in Fowl

              	
                European
      Patent Office

              	
                23-Nov-05

              	
                5849894

              	 
      	 
      
	
                Prevention
      of Respiratory Infections in Fowl

              	
                Singapore

              	
                27-Jan-05

              	
                200500467-6

              	 
      	 
      
	
                Prevention
      of Respiratory Infections in Fowl

              	
                Thailand

              	
                11-Feb-05

              	
                97659

              	 
      	 
      
	
                Prevention
      of Respiratory Infections in Fowl

              	
                Patent
      Cooperation Treaty

              	
                23-Nov-05

              	
                PCT/US05/042601

              	 
      	 
      
	
                Prevention
      of Respiratory Infections in Fowl

              	
                United
      States of America

              	
                3-July-07

              	
                11/795,659

              	 
      	 
      
	
                Prevention
      of Respiratory Infections in Fowl

              	
                Australia

              	
                23-Nov-05

              	
                2005323304

              	 
      	 
      
	
                Prevention
      of Respiratory Infections in Fowl

              	
                Japan

              	
                23-Nov-05

              	
                2007-549376

              	 
      	 
      
	
                Prevention
      of Respiratory Infections in Fowl

              	
                Canada

              	
                23-Nov-05

              	
                2,593,232

              	 
      	 
      
	
                Prevention
      of Respiratory Infections in Fowl

              	
                Vietnam

              	
                5-May-05

              	
                1-2005-00599

              	 
      	 
      
	
                Treatment
      of Skin Diseases

              	
                European
      Patent Office

              	
                15-Dec-05

              	
                5854144.2

              	 
      	 
      
	
                Treatment
      of Skin Diseases

              	
                Singapore

              	
                27-Jan-05

              	
                200500466-8

              	 
      	 
      
	
                Treatment
      of Skin Diseases

              	
                Vietnam

              	
                5-May-05

              	
                1-2005-00598

              	 
      	 
      
	
                Treatment
      of Skin Diseases

              	
                Thailand

              	
                25-Feb-05

              	
                98080

              	 
      	 
      
	
                Treatment
      of Skin Diseases

              	
                Canada

              	
                15-Dec-05

              	
                2594517

              	 
      	 
      
	
                Treatment
      of Skin Diseases

              	
                Australia

              	
                15-Dec-05

              	
                2005324417

              	 
      	 
      
	
                Treatment
      of Skin Diseases

              	
                Patent
      Cooperation Treaty

              	
                15-Dec-05

              	
                PCT/US05/045369

              	 
      	 
      
	
                Treatment
      of Skin Diseases

              	
                United
      States of America

              	
                11-Jul-07

              	
                11/795,044

              	 
      	 
      
	
                Method
      to Promote Wound Healing

              	
                European
      Patent Office

              	
                25-Oct-05

              	
                5813067.5

              	 
      	 
      
	
                Method
      to Promote Wound Healing

              	
                Australia

              	
                25-Oct-05

              	
                2005299341

              	 
      	 
      
	
                Method
      to Promote Wound Healing

              	
                Japan

              	
                25-Oct-05

              	
                2007-539081

              	 
      	 
      
	
                Method
      to Promote Wound Healing

              	
                Canada

              	
                25-Oct-05

              	
                2585265

              	 
      	 
      
	
                Method
      to Promote Wound Healing

              	
                Patent
      Cooperation Treaty

              	
                25-Oct-05

              	
                PCT/US05/038646

              	 
      	 
      
	
                Method
      to Promote Wound Healing

              	
                United
      States of America

              	
                27-Apr-07

              	
                11/666,474

              	 
      	 
      
	
                Treatment
      for Asthma

              	
                Patent
      Cooperation Treaty

              	
                31-Mar-06

              	
                PCT/US06/011833

              	 
      	 
      
	
                Treatment
      for Asthma

              	
                European
      Patent Office

              	
                31-Mar-06

              	
                6748998.9

              	 
      	 
      
	
                Treatment
      for Asthma

              	
                Japan

              	
                31-Mar-06

              	
                2008-504408

              	 
      	 
      
	
                Treatment
      for Asthma

              	
                Australia

              	
                31-Mar-06

              	
                Tba

              	 
      	 
      
	
                Treatment
      for Asthma

              	
                Canada

              	
                31-Mar-06

              	
                2,603,808

              	 
      	 
      
	
                Treatment
      for Asthma

              	
                Singapore

              	
                24-Jun-05

              	
                200504104-1

              	 
      	 
      
	
                Treatment
      for Asthma

              	
                United
      States of America

              	
                25-Sep-07

              	
                11/887,105

              	 
      	 
      
	
                Stimulation
      of Hair Growth

              	
                United
      States of America

              	
                20-Jun-05

              	
                10/539,734

              	 
      	 
      
	
                Stimulation
      of Hair Growth

              	
                Patent
      Cooperation Treaty

              	
                18-Dec-03

              	
                PCT/US03/040259

              	 
      	 
      
	
                Inducing
      and Maintaining Hair Color

              	
                United
      States of America

              	
                25-Oct-06

              	
                11/587,594

              	 
      	 
      
	
                Inducing
      and Maintaining Hair Color

              	
                Patent
      Cooperation Treaty

              	
                18-Apr-05

              	
                PCT/US05/013112

              	 
      	 
      
	
                Anti-Aging
      Effects of Substance P

              	
                Patent
      Cooperation Treaty

              	
                18-Apr-05

              	
                PCT/US05/013113

              	 
      	 
      
	
                Anti-Aging
      Effects of Substance P

              	
                Japan

              	
                18-Apr-05

              	
                2007-509540

              	 
      	 
      
	
                Anti-Aging
      Effects of Substance P

              	
                Canada

              	
                18-Apr-05

              	
                Tba

              	 
      	 
      
	
                Anti-Aging
      Effects of Substance P

              	
                United
      States of America

              	
                25-Oct-06

              	
                11/587,595

              	 
      	 
      
	
                Anti-Aging
      Effects of Substance P

              	
                European
      Patent Office

              	
                18-Apr-05

              	
                5755488.3

              	 
      	 
      
	
                Anti-Aging
      Effects of Substance P

              	
                China

              	
                18-Apr-05

              	
                2005-80016786.5

              	 
      	 
      
	
                Anti-Aging
      Effects of Substance P

              	
                Australia

              	
                18-Apr-05

              	
                2005240026

              	 
      	 
      
	
                Method
      to Reduce the Risk and/or Severity of Anthrax Infection

              	
                Patent
      Cooperation Treaty

              	
                6-Mar-07

              	
                PCT/US07/005668

              	 
      	 
      
	
                Method
      to Reduce the Risk and/or Severity of Anthrax Infection

              	
                United
      States of America

              	
                6-Mar
      07

              	
                Tba

              	 
      	 
      
	
                Prophylactic
      and Therapeutic Treatment of Mammals for Avian Influenza Virus
      Infection

              	
                Patent
      Cooperation Treaty

              	
                14-Aug-07

                 

              	
                PCT/US07/017953

                 

              	 
      	 
      
	
                Prophylactic
      and Therapeutic Treatment of Mammals for Avian Influenza Virus
      Infection

              	
                United
      States of America

                 

              	
                14-Aug-07

              	
                Tba

              	 
      	 
      
	
                Method
      to Treat Blood Cell Depletion

              	
                Patent
      Cooperation Treaty

              	
                30-May-07

              	
                PCT/US07/012661

              	 
      	 
      
	
                Method
      to Treat Blood Cell Depletion, In Conditions Such as MDS

              	
                United
      States of America

              	
                27-Jul-07

              	
                60/952,394

              	 
      	 
      
	
                Methods
      of Using Substance P Analogs to Ameliorate Myelodysplastic
      Syndrome

              	
                United
      States of America

              	
                27-Mar-08

              	
                61/039,867

              	 
      	 
      
	
                Methods
      of Using Substance P Analogs to Ameliorate Myelodysplastic
      Syndrome

              	
                United
      States of America

              	
                Tba

              	 
      	 
      	 
      
	
                Method
      to Stimulates Blood Cells Regeneration Following Non-Lethal Radiation
      Exposure

              	
                United
      States of America

                 

              	
                30-Jul-07

                 

              	
                60/952,691

                 

              	 
      	 
      
	
                Method
      to Treat Chemotherapy and Therapeutic Radiation
      Myelosuppression

              	
                United
      States of America

                 

              	
                tba

              	 
      	 
      	 
      
	
                Methods
      of Using Substance P Analogs in Radiation Oncology

              	
                United
      States of America

              	
                27-Mar-08

              	
                61/039,860

              	 
      	 
      
	
                Substance
      P and Analogs Thereof as an Immunogenic
      Composition  Adjuvant

              	
                United
      States of America

              	
                18-Jan-08

              	
                12/015,914

              	 
      	 
      
	
                Substance
      P and Analogs Thereof as an Immunogenic
      Composition  Adjuvant

              	
                Patent
      Cooperation Treaty

              	
                14-Aug-07

              	
                PCT/US08/000621

              	 
      	 
      
	
                Methods
      of Using Substance P and Analogs for Ameliorating Adverse Effects of
      Drugs

              	
                United
      States of America

              	
                20-Aug-07

              	
                60/965,580

              	 
      	 
      
	
                Methods
      of Using Substance P and Analogs for Ameliorating Drug Induced Blood
      Dyscrasias

              	
                United
      States of America

              	
                27-Mar-08

              	
                61/039,866

              	 
      	 
      
	
                Substance
      P Analogs as PARP Inhibitors

              	
                United
      States of America

              	
                29-Aug-07

              	
                60/966,948

              	 
      	 
      
	
                Substance
      P Analogs to Promote Cell Differentiation

              	
                United
      States of America

              	
                2-Oct-07

              	
                60/997,314

              	 
      	 
      
	
                Methods
      of Stimulating the Proliferation and/or Differentiation of Stem Cells with
      Substance P, or an Analog

                 

              	
                United
      States of America

                 

              	
                26-Oct-07

              	
                60/983,012

                 

              	 
      	 
      
	
                Methods
      of Using Substance P Analogs for Stem Cell Growth

              	
                United
      States of America

              	
                24-Mar-08

              	
                61/038,871

              	 
      	 
      
	
                Methods
      of Using Substance P Analogs for Stem Cell Growth

              	
                United
      States of America

              	
                26-Mar-08

              	
                61/039,686

              	 
      	 
      
	
                Methods
      of Using Substance P Analogs for Stem Cell Growth

              	
                United
      States of America

              	
                Tba

              	 
      	 
      	 
      
	
                Substance
      P Analogs to Stimulate Fibroblast Growth

              	
                United
      States of America

              	
                12-Oct-07

              	
                60/979,769

              	 
      	 
      
	
                Methods
      and Compositions for Stimulation of Fibroblasts

              	
                United
      States of America

              	
                24-Apr-08

              	
                61/047,709

              	 
      	 
      
	
                Methods
      and Compositions for Stimulation of Fibroblasts

              	
                United
      States of America

              	
                tba

              	 
      	 
      	 
      
	
                Methods
      and Compositions for Improving the Texture or Appearance of Skin with
      Substance P or an Analog Thereof

              	
                United
      States of America

                 

              	
                21-Dec-07

              	
                61/016,245

              	 
      	 
      
	
                Methods
      and Compositions for Improving the Texture or Appearance of Skin with
      Substance P or an Analog Thereof

              	
                United
      States of America

              	
                14-Feb-08

              	
                61/028,774

              	 
      	 
      
	
                Methods
      of Ex Vivo Expansion of Bone Marrow Cells Using Substance P and Analogs
      Thereof

              	
                United
      States of America

              	
                29-Jan-08

              	
                61/024,354

              	 
      	 
      
	
                Substance
      P and Analogs thereof as a Cancer Immunogenic Composition
      Adjuvant

              	
                United
      States of America

              	
                17-Apr-08

              	
                61/045,856

              	 
      	 
      
	
                ELISA
      for Substance P Analogs

              	 
      	
                Tba